Odelia Cooper
Overview
Explore the profile of Odelia Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tal N, Bannykh S, Learch T, Mamelak A, Cooper O
JCEM Case Rep
. 2025 Feb;
3(2):luaf001.
PMID: 39911682
Cushing syndrome (CS) results from prolonged exposure to excess glucocorticoids, leading to a range of clinical manifestations including avascular necrosis (AVN), a rare complication of CS. Although AVN is often...
2.
Dery L, Shimon I, Rudman Y, Iraqi H, Kushnir S, Shochat T, et al.
J Endocrinol Invest
. 2024 Oct;
48(3):691-699.
PMID: 39476176
Purpose: Given prolactin's (PRL) multifaceted roles in mammary tissue, an association between hyperprolactinemia and breast cancer has been hypothesized. Despite previous studies not identifying this risk, we aimed to investigate...
3.
Cooper O, Lis R, Bonert V, Labadzhyan A, Liu N, Ben-Shlomo A, et al.
J Clin Endocrinol Metab
. 2023 Feb;
108(8):e623-e633.
PMID: 36723998
Context: Postoperative hyponatremia leads to prolonged hospital length of stay and readmission within 30 days. Objective: To assess 3 strategies for reducing rates of postoperative hyponatremia and analyze risk factors...
4.
Cooper O, Bonert V, Mamelak A, Bannykh S, Melmed S
Neurosurgery
. 2022 Mar;
90(6):775-783.
PMID: 35262532
Background: Predictive markers of aggressive pituitary tumors have not been consistently demonstrated. Dural invasion and invasion-associated proteins, including matrix metalloproteinase-9 (MMP9) and cofilin, have been proposed to predict aggressive behavior...
5.
Cooper O, Bonert V, Liu N, Mamelak A
Front Endocrinol (Lausanne)
. 2021 Dec;
12:725014.
PMID: 34867776
Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous evidence supporting available treatment approaches. Recent guidelines emphasize the need to maximize standard therapies as well as...
6.
Sankar K, Macfarlane M, Cooper O, Falk J
Cureus
. 2021 Nov;
13(10):e18983.
PMID: 34820238
Diabetic ketoacidosis (DKA) is a commonly encountered diagnosis in the general inpatient and intensive care unit settings. We report a rare case of pembrolizumab-induced DKA in a patient with bladder...
7.
Cooper O, Bonert V, Rudnick J, Pressman B, Lo J, Salvatori R, et al.
J Clin Endocrinol Metab
. 2020 Nov;
106(2):e917-e925.
PMID: 33150390
Context: Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior. Objective: We evaluated lapatinib, an ErbB1-epidermal growth factor...
8.
Araki T, Cooper O, Fukuoka H
Front Endocrinol (Lausanne)
. 2019 Jun;
10:358.
PMID: 31214126
No abstract available.
9.
Cooper O, Greenman Y
Front Endocrinol (Lausanne)
. 2018 Sep;
9:469.
PMID: 30186234
Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing...
10.
Ben-Shlomo A, Cooper O
Pituitary
. 2018 Jan;
21(2):183-193.
PMID: 29344907
Purpose: Silent corticotroph adenomas (SCAs) present clinically as non-functioning adenomas (NFAs) but are immunopositive for adrenocorticotrophic hormone (ACTH) without biochemical and clinical manifestation of hypercortisolism. Pathologic examination of resected NFAs...